Detalles del proyecto
| Estado | Finalizado |
|---|---|
| Fecha de inicio/Fecha fin | 4/12/12 → 8/21/23 |
Financiación
- Celgene: 195.666,00 US$
A Phase 3 Open-Label Randomized Study to Compare the Efficacy And Safety of Rituximab Plus lenalidomide (CC-5013) versus Rituximab Plus Chemotherapy in Subjects with Previously Untreated Follicular Lymphoma
- Fleischman, Roger (PI)
- Monohan, Gregory (CoI)
- Hayslip, John (Former PI)
- Shakil, Shams (Former CoI)